India - Kiingereza - Central Drugs Standard Control Organization

reaal hc. - soap - 75gm

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o), vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t), sodium ascorbate (unii: s033eh8359) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), n - multi-vit-flor (multivitamin with 0.25 mg, 0.5 mg and 1 mg of fluoride) chewable tablet multivitamin and fluoride supplement ingredients: sucrose, sorbitol, fructose, citric acid, beet root juice, carrageenan, grape flavor, raspberry flavor, stearic acid, cherry flavor, magnesium stearate, sucralose.

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - chlorzoxazone (unii: h0de420u8g) (chlorzoxazone - unii:h0de420u8g) - chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. chlorzoxazone does not directly relax tense skeletal muscles in man. chlorzoxazone is contraindicated in patients with known intolerance to the drug.

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - chlorzoxazone (unii: h0de420u8g) (chlorzoxazone - unii:h0de420u8g) - chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. chlorzoxazone does not directly relax tense skeletal muscles in man. chlorzoxazone is contraindicated in patients with known intolerance to the drug.

Marekani - Kiingereza - NLM (National Library of Medicine)

spirit pharmaceuticals llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic • hand sanitizer to help reduce bacteria on the skin that potentially can cause disease • recommend for repeated use

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone tablets is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - phenobarbital sodium (unii: sw9m9bb5k3) (phenobarbital - unii:yqe403bp4d) - - sedative. sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. however, thyrotoxic individuals occasionally react poorly to barbiturates. - hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see clinical pharmacology ). - preanesthetic. - long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatmen

Marekani - Kiingereza - NLM (National Library of Medicine)

cameron pharmaceuticals - phenobarbital sodium (unii: sw9m9bb5k3) (phenobarbital - unii:yqe403bp4d) - barbiturates are contraindicated in patients with known barbiturate sensitivity. barbiturates are also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver functions or with severe respiratory distress where dyspnea or obstruction is evident. large doses are contraindicated in nephritic subjects. barbiturates should not be administered to persons with known previous addiction to the sedative-hypnotic group since ordinary doses may be ineffectual and may contribute to further addiction. intraarterial administration is contraindicated. its consequences vary from transient pain to gangrene. subcutaneous administration produces tissue irritation, ranging from tenderness and redness to necrosis and is not recommended. (see dosage and administration, treatment of adverse effects due to inadvertent error in administration .) phenobarbital sodium injection contains the preservative benzyl alcohol and is not recommended for use in neonates. there have been reports of f

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - flunixin as flunixin meglumine - parenteral liquid/solution/suspension - flunixin as flunixin meglumine benzene active 50.0 mg/ml - musculoskeletal system - cattle | dog | horse | pigs | beef | bitch | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | castra - analgesic | anti-inflammatory agent | antiprostaglandin | antipyretic | non steroidal | antipyretic | bone soreness | bruising | bursitis | colic | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle relaxant | muscle soreness | osteoarthritis | platelet activity | rheumatism | sedative | spasmolytic | sprains | strains | tendon sprains | traumatic swelling